Skip to main content

Table 3 Efficacy evaluation

From: A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Patient no. Evaluation (RECIST ver 1.1) Time to response (days) Duration of response (days) PFS (days) OS (days)
Target response Overall response Surgical response
Cohort 1 HF-1-02 SD PD     119 150
HF-1-04 SD PD     91 465
HF-1-05 PR PR CR 48 288 335 611
Cohort 2 HF-2-01 SD SD     663 1211
HF-2-02 PR PR CR 13 444 456 1189
HF-2-03 SD SD     48 336
Cohort 3 HF-3-02 SD SD     217 694
HF-3-03 SD SD     69 273
HF-3-04 PR PR   34 156 189 255
  1. PFS progression free survival, OS overall survival, PR partial response, SD stable disease, CR complete response